66405-41-2

Usage

Uses

Used in Pharmaceutical Industry:
(4-OXO-CYCLOHEXYL)-ACETIC ACID METHYL ESTER is used as a precursor for the synthesis of bioactive molecules, contributing to the development of new drugs and therapeutic agents.
Used in Agrochemical Industry:
(4-OXO-CYCLOHEXYL)-ACETIC ACID METHYL ESTER is used as a key intermediate in the production of various agrochemicals, such as pesticides and herbicides, to enhance crop protection and yield.
Used in Organic Synthesis:
(4-OXO-CYCLOHEXYL)-ACETIC ACID METHYL ESTER is used as a building block in organic synthesis, enabling the creation of complex organic compounds for various applications, including pharmaceuticals, agrochemicals, and other specialty chemicals.
It is important to handle (4-OXO-CYCLOHEXYL)-ACETIC ACID METHYL ESTER with care, as it may pose health risks. Safe handling procedures and guidelines should be followed to ensure the safety of individuals working with (4-OXO-CYCLOHEXYL)-ACETIC ACID METHYL ESTER.

InChI:InChI=1/C9H14O3/c1-12-9(11)6-7-2-4-8(10)5-3-7/h7H,2-6H2,1H3

Upstream product

• 91158-10-0 4-(Carbomethoxymethylene)cyclohexanone 
• 14199-15-6 Methyl 4-hydroxyphenylacetate 
• 637-88-7 1,4-Cyclohexanedione 
• 317338-46-8 methyl 2-(1,4-dioxaspiro[4.5]decan-8-yl)acetate 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 172270-85-8 8-(methoxyformylmethylene)-1,4-dioxaspiro[4.5]decane 
• 99183-13-8 methyl 2-(4-hydroxycyclohexyl)acetate 

Downstream Products

• 7171-78-0 <4-Methyl-cyclohexen-(3)-yl>-essigsaeure-methylester 
• 214202-83-2 methyl (4-propylidenecyclohexyl)acetate 
• 886587-62-8 {4-[bis-(4-hydroxy-phenyl)-methylene]-cyclohexyl}-acetic acid methyl ester 
• 1041046-51-8 C₁₂H₁₉NO₂ 
• 52263-23-7 4-oxocyclohexaneacetic acid 
• 1109277-67-9 methyl 2-(4-(((trifluoromethyl)sulfonyl)oxy)cyclohex-3-en-1-yl)acetate 
• 1236046-26-6 methyl 2-(4-hydroperoxy-4-methoxycyclohexyl)acetate 
• 1227734-54-4 methyl 2-[4-(methoxyimino)cyclohexyl]acetate 
• 1190076-26-6 (4-methylamino-cyclohexyl)-acetic acid methyl ester 
• 32863-01-7 4-(2-hydroxyethyl)cyclohexan-1-one 
• 1124174-16-8 methyl 2-((1r,4r)-4-hydroxycyclohexyl)acetate 
• 1268239-62-8 C₂₆H₂₉F₂N₃O₅ 
• 1268239-16-2 trans-6-[3-(2,3-difluoro-phenyl)-ureido]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester 
• 1268239-40-2 trans-6-[3-(2-chloro-3-methyl-phenyl)-ureido]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester 

Relevant academic research and scientific papers

A practical synthesis of a potent and selective diacylglycerol acyltransferase-1 (DGAT-1) inhibitor

A practical synthesis of a potent, selective, and orally efficacious diacylglycerol acyltransferase-1 (DGAT-1) inhibitor, is described. This synthesis is suitable for multi-kilogram scale with high regioselectivity and stereoselectivity. The synthesis inv

Continuous Synthesis of Aryl Amines from Phenols Utilizing Integrated Packed-Bed Flow Systems

Aryl amines are important pharmaceutical intermediates among other numerous applications. Herein, an environmentally benign route and novel approach to aryl amine synthesis using dehydrative amination of phenols with amines and styrene under continuous-flow conditions was developed. Inexpensive and readily available phenols were efficiently converted into the corresponding aryl amines, with small amounts of easily removable co-products (i.e., H2O and alkanes), in multistep continuous-flow reactors in the presence of heterogeneous Pd catalysts. The high product selectivity and functional-group tolerance of this method allowed aryl amines with diverse functional groups to be selectively obtained in high yields over a continuous operation time of one week.

IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS

A compound according to formula I in the form of any one of its stereoisomers or a mixture thereof (l) wherein is indicating a carbon-carbon single or double bond, with the provision that the compound has one carbon-carbon double bond or two isolated or c

Construction of Morphan Derivatives by Nitroso–Ene Cyclization: Mechanistic Insight and Total Synthesis of (±)-Kopsone

A type II nitroso–ene cyclization was developed for the construction of morphan derivatives with good functional-group tolerance. DFT calculations revealed that the nitroso–ene reaction proceeds in a stepwise manner involving diradical or zwitterionic intermediates. The rate-determining step is C?N bond formation, followed by a rapid hydrogen-transfer step with a chair-conformation transition state. The current approach was also successfully applied in the first total synthesis of (±)-kopsone, a highly strained yet simple morphan-type alkaloid isolated from Kopsia macrophylla.

A biocatalytic/reductive etherification approach to substituted piperidinyl ethers

A synthetically useful protocol has been developed for the preparation of highly functionalized piperidinyl ethers. Biocatalytic reduction of cyclhexanones 7, 10, and 14 allows for the preparation of both cis- and trans diastereomers with an extremely high degree of stereochemical control. Reductive etherification of the corresponding trimethylsilylethers with 1-(benzyloxycarbonyl)-4-piperidinone 17 in the presence of triethylsilane and catalytic TMSO-Tf provides the desired piperidinyl ethers in good to excellent yields. Finally hygrogenolysis of the nitrogen protecting group leads to piperidinyl ethers in near quantitative yields. Application of the methodology to a range of piperidinyl ethers, including the core scaffolds of diphenylpyraline and ebastine, is also described.

PYRIDINE DERIVATIVES AS DGAT-1 INHIBITORS

Described herein are compounds of formula (I): The compounds of formula (I) act as DGAT1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.

NOVEL TETRAHYDROISOQUINOLINE COMPOUNDS

The present invention relates to a compound or a pharmacologically acceptable salt thereof having an excellent DGAT inhibitory effect and feeding suppressant effect. The present invention provides trans-6-[3-(2,4-difluoro-phenyl)-ureido]-3,4-dihydro-1H-is

PROCESS FOR THE PREPARATION OF DISPIRO 1,2,4-TRIOXOLANE ANTIMALARIALS (OZ277)

This invention relates to an improved process for the preparation of a compound of Formula (I), salts of the free base cis-adamantane-2-spiro-3′-8′-[[[(2′-amino-2′-methyl propyl)amino]carbonyl]methyl]-1′,2′,4′-trioxaspiro[4.5]decane wherein X can be an an

NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE

The present invention relates to a compound or a pharmacologically acceptable salt thereof having an excellent DGAT inhibitory effect and feeding suppressant effect. The present invention provides a compound represented by the general formula (I), or pharmacologically acceptable salt thereof: [wherein, R1 represents a phenylaminocarbonyl group that may be substituted with 1 to 5 group(s) independently selected from Substituent Group A, a benzoxazol-2-yl group that may be substituted with 1 to 3 group(s) independently selected from Substituent Group A, or the like; R2 independently represents a C1-C6 alkyl group; R3 represents a group represented by the formula -C(=O)-O-R4 or the like; R4 represents a hydrogen atom, a C1-C6 alkyl group that may be substituted with 1 to 3 group(s) independently selected from Substituent Group B, or the like; X represents an oxygen atom, a methylene group, or a group represented by the formula -NH-, or the like; L represents a single bond, a methylene group, or the like;...... represents a single bond or a double bond; m represents 1 or 2; n represents an integer of 0 to 5; Substituent Group A represents a halogen atom, a C1-C6 alkyl group, a C1-C6 halogenated alkyl group, a C1-C6 alkoxy group, or the like; and Substituent Group B represents a C3-C6 cycloalkyl group, a phenyl group, a carboxyl group, or the like].

SUBSTITUTED BICYCLOLACTAM COMPOUNDS

The invention provides compounds of formula (1), and the pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5a, R5b, R5c, R5d, Q, A, Z, and R7 /s